Log in to save to my catalogue

803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with se...

803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with se...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2955270976

803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-OVAR 2.21 phase III trial

About this item

Full title

803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-OVAR 2.21 phase III trial

Publisher

Kidlington: BMJ Publishing Group Ltd

Journal title

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A38-A39

Language

English

Formats

Publication information

Publisher

Kidlington: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

Introduction/BackgroundAGO-OVAR 2.21 is the first phase III trial in recurrent ovarian cancer that compared two bevacizumab-containing combination chemotherapy regimens independent of prior anti-angiogenic therapy. As safety and efficacy data on bevacizumab re-challenge is limited, this present exploratory analysis focuses on patients with prior an...

Alternative Titles

Full title

803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-OVAR 2.21 phase III trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2955270976

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2955270976

Other Identifiers

ISSN

1048-891X

E-ISSN

1525-1438

DOI

10.1136/ijgc-2024-ESGO.48

How to access this item